This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics
of inhaled TD-0903 compared with a matching placebo in combination with standard of care
(SOC) in hospitalized patients with confirmed COVID-19 associated acute lung injury and
impaired oxygenation.